Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Cost Effectiveness of Newer Antiviral Agents for Herpes Zoster: Is the Evidence Spotty?

Kenneth J. Smith and Mark S. Roberts
The Journal of Infectious Diseases
Vol. 178, Supplement 1. The Third International Conference on the Varicella-Zoster Virus (Nov., 1998), pp. S85-S90
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30113888
Page Count: 6
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Cost Effectiveness of Newer Antiviral Agents for Herpes Zoster: Is the Evidence Spotty?
Preview not available

Abstract

Famciclovir and valaciclovir were approved for use in the treatment of herpes zoster despite controversy over antiviral therapy in zoster due to high costs and uncertain benefits. To explore these issues, a Markov decision model was developed, and the incremental cost effectiveness of antiviral treatment for herpes zoster was estimated using these agents compared with no antiviral therapy. A third-party payer perspective was taken. Sensitivity analyses were performed, modeling differences in antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness parameters. Treatment of severely symptomatic acute zoster was found reasonable from a cost-effectiveness standpoint in base-case and worst-case scenarios. Treatment of mildly symptomatic acute zoster was more expensive but would likely be considered cost effective in scenarios where PHN risk was higher, PHN duration longer, or antiviral shortening of PHN greater. Further research comparing antiviral efficacy in herpes zoster is needed.

Page Thumbnails

  • Thumbnail: Page 
S85
    S85
  • Thumbnail: Page 
S86
    S86
  • Thumbnail: Page 
S87
    S87
  • Thumbnail: Page 
S88
    S88
  • Thumbnail: Page 
S89
    S89
  • Thumbnail: Page 
S90
    S90